Clinical Trials List
2016-02-01 - 2027-05-31
Phase III
Recruiting3
ICD-10C79.10
Secondary malignant neoplasm of unspecified urinary organs
ICD-10C79.11
Secondary malignant neoplasm of bladder
ICD-10C79.19
Secondary malignant neoplasm of other urinary organs
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9198.1
Secondary malignant neoplasm of other urinary organs
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- CHUNG-HSIN CHEN Division of Hematology & Oncology
- YU-CHUAN LU Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- JHE-CYUAN GUO Division of Hematology & Oncology
- Yeong-Shiau Pu Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
- - - Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Che-Hung Lin Division of Hematology & Oncology
- Wei-Ching Lin Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ching-Chia Li Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
12 participants
-
Global
700 participants
